SLC28A2 (concentrative nucleoside transporter 2, CNT2) is a sodium-dependent, purine-selective transporter that mediates cellular uptake of purine nucleosides and uridine 1. The transporter exhibits N1/cif subtype characteristics, selectively recognizing purine nucleosides while showing preference for inosine, ribavirin, and uridine as substrates 234. SLC28A2 plays a critical role in purine nucleoside salvage pathways across tissues including kidney, intestine, and liver, contributing to nucleotide biosynthesis and regulating organic compound transport in specialized tissues 1. Genetic variants in SLC28A2 have significant clinical implications. Promoter polymorphisms, particularly rs2413775 (-146T>A), enhance transcriptional activity through altered hepatic nuclear factor 1 binding, potentially affecting nucleoside analog pharmacokinetics 5. In gout etiology, rs2271437 and rs16941238 variants associate with serum uric acid levels and hyperuricemia susceptibility in Han Chinese populations 6. Additionally, SLC28A2 rs11854484 genotypes predict clinically significant anemia in hepatitis C patients receiving protease inhibitor-ribavirin therapy 7. High SLC28A2 expression correlates with poor responses to neoadjuvant chemoradiotherapy in rectal cancer and serves as an independent prognostic marker for disease-specific survival 8. These findings establish SLC28A2 as both a nucleoside salvage facilitator and a genetic determinant of drug response and disease susceptibility.